| Kendra Denise Sublett, MSN, APRN, FNP-C | |
|
125 Kingswood Dr, Campbellsville, KY 42718-9634 | |
| (270) 789-1112 | |
| (270) 789-6176 |
| Full Name | Kendra Denise Sublett |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 125 Kingswood Dr, Campbellsville, Kentucky |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649991662 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 3018315 (Kentucky) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | 3018315 (Kentucky) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kendra Denise Sublett, MSN, APRN, FNP-C 1698 Old Lebanon Rd, Campbellsville, KY 42718-3319 Ph: (270) 789-6087 | Kendra Denise Sublett, MSN, APRN, FNP-C 125 Kingswood Dr, Campbellsville, KY 42718-9634 Ph: (270) 789-1112 |
News Archive
Teva Pharmaceutical Industries Ltd. today announced the European launch of Life Effects (https://lifeeffects.teva), a patient-centric website hosting content created by patients and checked by experts, at the European Committee for the Treatment and Research of Multiple Sclerosis Congress in Berlin.
Health Dialog Services Corporation, a leading provider of healthcare decision programs, today announced that its client, Capital District Physicians' Health Plan, Inc. (CDPHP®), has been recognized by the Health Industries Research Cos. (HIRC) for offering the best disease management program in upstate New York.
A research team based at the University of Chicago has overcome challenges that have limited gene therapy and demonstrated how their novel approach with skin transplantation could enable a wide range of gene-based therapies to treat many human diseases.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced favorable response and safety indications from a group of patients with advanced solid tumors (principally soft tissue sarcomas) in the Company's ongoing Phase 1b/2 clinical trial with INNO-206, its tumor-targeting conjugate of the commonly used chemotherapeutic agent doxorubicin.
The last time lawmakers repealed a major piece of health care legislation was more than 20 years ago, when vehement opposition to a 1988 measure providing new Medicare prescription drug coverage in exchange for higher income taxes led to repeal 16 months later, CQ HealthBeat reports. Polls are more evenly divided on the newest health care overhaul, and due to the law's unprecedented complexity, "efforts to unwind the measure are as fragmented as the health care system itself."
› Verified 2 days ago